Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Technology search

show all patents

Technology search by keyword

Results 1 - 8 of 8

Müller, Zhao, Ottonello

Combined prophylactic and therapeutic Vaccines of HPV (P-1382)

Keywords: Therapeutics, Vaccines

Cervical cancer is women?s second most frequent cancer worldwide. Clinical and molecular studies have shown that certain types of HPV, referred to as high-risk types, are the etiological agents of this disease. Two anti-HPV virus-like particles (VLPs) vaccines for the prophylaxis of cervical cancer are on the market (Merck: GardasilTM and GlaxoSmithKline: CervarixTM). We developed a vaccine which is composed of an immunogenic polypeptide comprising (i) a B-cell epitope of HPV, (ii) a T-cell epitope of HPV, and (iii) the scaffold polypeptide thioredoxine. The vaccine can be used in prophylactic and therapeutic approaches against infections with human papillomaviruses. more...

Hoppe-Seyler, Braun, Hoppe-Seyler

Iron Chelators in Tumor Therapy (P-1361)

Keywords: Therapeutics

We invented a pharmaceutically compatible iron chelator or a pro-drug thereof for use in treating and/or preventing cancer in a patient suspected or known to comprise hypoxic cancer cells, and use in treatment and/or prevention of a human papillomavirus (HPV) related lesion. The technology further allows the use of an iron chelator or prodrug thereof for inducing senescence in a cancer cell, preferably a hypoxic cancer cell; and to a method for inducing an irreversible proliferation arrest in cancer cells comprising a) contacting said cancer cells with an iron chelator or prodrug thereof and, thereby, b) inducing an irreversible proliferation arrest in said cancer cells. more...

Müller, Ottonello, Bolchi, Mariz, Balz, Zhao

Cutaneous human Papilloma Virus Vaccine (P-1358)

Keywords: Therapeutics, Vaccines

Infections with human papillomavirus (HPV) are a worldwide health challenge, particularly in resource-limited regions. HPV-related diseases are pre-malignancies or overt malignancies of the skin and mucosal surfaces and are an important personal and public health problem causing physical, mental, sexual and financial detriments. The World Health Organization estimates that there are approximately 14 million new HPV infections each year. We have developed an immunogenic polypeptide comprising a multitude of papilloma-virus (PV) L2 N-terminal peptides to protect against most cutaneous HPV types. more...

Amtmann, Gunkel, Miller, Morgen

Treatment of chemotherapy-resistant Small Cell Lung Cancer (P-1306)

Keywords: Therapeutics

Lung cancer is the leading cause of death among men and women in North America and attracts substantial pharmaceutical investment. However, in contrast to non-small cell lung cancer (NSCLC) therapies, where significant progress has been made with targeted agents and immunotherapies, the small cell lung cancer (SCLC) landscape has remained static for more than 30 years. However, we have shown that cyclodextrin stimulates the anti-tumor effect of combinations of disulfiram with various heavy metal salts. Surprisingly, the tested T-cell lymphoma/leukemia, carcinoma, non-T-cell leukemia and SCLC cells are hypersensitive to the combination treatment in cyclodextrin formulation. more...

Heikenwälder, Zender, Weber

Treatments of Non-Alcoholic Steatohepatitis (NASH) and HCC (P-1305)

Keywords: Therapeutics

Non-alcoholic fatty liver disease (NAFLD), comprising several liver diseases including NAFL and NASH, which is the most frequent liver disease world-wide, is a clinical manifestation of overweight and metabolic syndrome. The prevalence of NAFL is increasing globally. We have identified compounds that are effective for treating non-alcoholic steatohepatitis (NASH), an advanced stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and hepatocellular carcinoma (HCC). more...


New Antibody against SUMO1 protein (P-1193)

Keywords: Therapeutics, Research Tools

The antibody of this invention is a mouse monoclonal antibody directed against SUMO176-86 recognizing SUMO1 of human, mouse, chicken and X. laevis. It is suitable for western blot and immune precipitation as well as for large-scale enrichment of SUMOylated species by IP / peptide elution.

Abdollahi, Lee, Javaherian

Oligomerization improves endostatin as antiangiogenic and anticancer drug (P-1000)

Keywords: Therapeutics

Endostatin is an antiangiogenic protein first discovered in Folkman’s laboratory at Childrens Hospital, Harvard Medical School, and Boston. The antitumor properties of this protein are well established. However, the amount of protein required for injection in patients was beyond production feasibility due to the poor pharmacokinetics of endostatin monomer. We have shown that the problem of poor pharmacokinetics can be solved by using the Fc domain of IgG being conjugated to endostatin, a component of all monoclonal antibodies approved for patients with a number of diseases including cancer. As a result of employing Fc-endostatin, the half-life in mice was increased to 2 weeks instead of 2 hours for endostatin alone, consistent with pharmacokinetics of monoclonal antibodies. more...

Platten, Bunse, Wick

Method for immunodiagnostic und immunotherapy of astrozytomes having IDH1R132H-mutation (P-987)

Keywords: Therapeutics

The technology can be used to detect cancer types with IDH1 R132H mutation in blood samples of patients. Furthermore, T-cells obtained from patients suffering from tumors accompanied by IDH1 R132H mutation can be stimulated using the peptide, which initiates via the peptide vaccine immune response against tumor cells. more...

to top
powered by webEdition CMS